Document:

EX-10.2

 Exhibit 10.2 

Confidential 
 Amendment #1 

 
 Cooperative Research and Development Agreement # 03111 

“Development and Evaluation of Precigen Inc.’s Proprietary Non-viral Sleeping Beauty Vectors for Genetic Modification of Peripheral Blood
Lymphocytes with Genes Encoding Mutated Tumor Neoantigen-specific T Cell Receptors (also referred to as Mutation Reactive T Cell Receptors) that Have Been Identified Using NCI Proprietary Methods” 

IC Principal Investigator: Steven A. Rosenberg, M.D., Ph.D. 

Collaborators: Precigen Inc. and ZIOPHARM Oncology, Inc. 
 The
purpose of this amendment is to change certain terms of the above-referenced Cooperative Research and Development Agreement (CRADA). These changes are reflected below, and except for these changes, all other provisions of the original CRADA
remain in full force and effect. Underlining indicates additions, and strikeout indicates deletions. 
 The Parties agree: 

 

	 	1.	 Intrexon Corporation transfers all operating capabilities pertinent to this CRADA to Precigen Inc., an Intrexon
wholly owned subsidiary. And thus, Intrexon assigns all its rights, titles, interests and benefits in and to CRADA #03111, along with its responsibilities under CRADA #03111, to Precigen Inc. 

 

	 	2.	 Intrexon Corporation is removed as the Collaborator, and Precigen Inc. is added as the Collaborator.

  

	 	3.	 The CRADA title is modified to read as follows: “Development and Evaluation of
Intrexon Corporation’s Precigen Inc.’s Proprietary Non-viral Sleeping Beauty Vectors for Genetic Modification of Peripheral Blood Lymphocytes with Genes Encoding Mutated Tumor Neoantigen-specific T Cell
Receptors (also referred to as Mutation Reactive T Cell Receptors) that Have Been Identified Using NCI Proprietary Methods”. 

  

	 	4.	 The CRADA abstract is modified to read as follows: The principal goal of this CRADA is to
Under a Cooperative Research and Development Agreement (CRADA), the National Cancer Institute (NCI), Precigen, Inc., and ZIOPHARM Oncology, Inc. will develop and evaluate adoptive cell transfer-based immunotherapies (ACT) using NCI
proprietary methods for the isolation of tumor-reactive T Cell Receptors (TCRs) targeting unique, patient specific mutated neoantigen(s) and introduction of said TCRs into T cell subsets isolated from peripheral blood using proprietary
Intrexon Corporation (“Intrexon”) Precigen Inc. Non-Viral Sleeping Beauty Transposon and Transposases for the treatment of patients with solid tumor malignancies. 

 

	 	5.	 Article 3.7.2 is amended to read as follows: 

 

	 	3.7.2	 When a Party files the IND, the other Party agrees to provide the filing party background data and information
necessary to support the IND 

  
 Page 1 of 4

 Confidential 
  

 

	 	in electronic Common Technical Document (eCTD) format. The Parties further agree to provide a letter of cross-reference to all data and pertinent regulatory filings sponsored by a Party under this
CRADA. Both Parties’ employees will be reasonably available to respond to inquiries from the FDA regarding information and data contained in the Party’s IND, DMF, other filings, or other information and data provided to one
Party by the other Party pursuant to this Article 3. 

  

	 	6.	 Article 3.11 is amended to read as follows: 

3.11 FDA Meetings/Communications. All formal meetings with the FDA concerning any clinical trial within the scope of the
Research Plan will be discussed by Collaborator and IC in advance. Each Party reserves the right to take part in setting the agenda for, to attend, and to participate in these meetings, as appropriate. Sponsor will provide the other
Party with copies of FDA meeting minutes, all transmittal letters for IND submissions, IND safety reports, formal questions and responses that have been submitted to the FDA, Annual Reports, and official FDA correspondence,
pertaining either to the INDs under this CRADA or to the Clinical Investigators on Protocols performed in accordance with the Research Plan, except to the extent that those documents contain the proprietary information of a third
party or dissemination is prohibited by law. 
  

	 	7.	 Article 4.1 is amended to read as follows: 

4.1 Interim Research and Development Reports. The CRADA PIs should exchange information regularly, in writing. This exchange may be
accomplished through meeting minutes, detailed correspondence, circulation of draft manuscripts, Steering Committee reports, copies of Annual Reports and any other reports updating the progress of the CRADA research. However, the Parties must
exchange updated Investigator’s Brochure, formulation and preclinical data, and toxicology findings, as they become available; these data and documents will be provided in eCTD format. 

 

	 	8.	 The IC’s Clinical Contact (as needed for Article 4.4.2) is amended to read as follows:

 Steven A. Rosenberg, M.D., Ph.D. 

Surgery Branch, NCI 
 10 Center
Drive, MSC 1201 
 Bldg. 10, CRC Room 3-3940 

Bethesda, MD 20892-1201 
 Tel:
[    ] 
 Fax: [    ] 

and 
 [    ]

  

  
 Page 2 of 4

 Confidential 
  

 

	 	9.	 Add in a new Article 8.9 (Certificate of Confidentiality) as follows: 

8.9 Certificate of Confidentiality. The CRADA Data collected under a Protocol conducted under this CRADA are covered under a Certificate
of Confidentiality that has been issued by the NIH pursuant to Section 301(d) of the Public Health Service Act (42 U.S.C. 241(d)). Under this Certificate of Confidentiality, the Collaborator may not: 

a) Disclose or provide, in any Federal, State, or local civil, criminal, administrative, legislative, or other proceeding, the name of such
individual or any such information, document, or biospecimen that contains identifiable, sensitive information about the individual and that was created or compiled for purposes of the research, unless such disclosure or use is made with
the consent of the individual to whom the information, document, or biospecimen pertains; or 
 b) Disclose or provide to any other person
not connected with the research the name of such an individual or any information, document, or biospecimen that contains identifiable, sensitive information about such an individual and that was created or compiled for purposes of the
research. 
 Provided that Collaborator will be permitted to disclose the information described in the points set forth above as follows:

 a) If required by Federal, State, or local laws (e.g., as required by the Federal Food, Drug, and Cosmetic Act, or state laws
requiring the reporting of communicable diseases to State and local health departments), excluding instances of disclosure in any Federal, State, or local civil, criminal, administrative, legislative, or other proceeding; 

b) If necessary for the medical treatment of the individual to whom the information, document, or biospecimen pertains and made with the
consent of such individual; 
 c) If made with the consent of the individual to whom the information, document, or biospecimen
pertains; or 
 d) If made for the purposes of other scientific research that is in compliance with applicable Federal regulations governing
the protection of Human Subjects in research. 
 Prior to making any permitted disclosures, Collaborator will ensure that that any recipient
of data protected by a Certificate of Confidentiality agrees to comply with the Certificate. 
 SIGNATURES ON THE NEXT PAGE 

  
 Page 3 of 4

 Confidential 
  

ACCEPTED AND AGREED TO: 
 For the National Cancer
Institute: 
  

							
	 /s/ James H. Doroshow
	 		 	          	 	 3/18/18

	James H. Doroshow, M.D.	 		 		 	Date
	Deputy Director for Clinical and Translational	 		 		 	
	Research, NCI	 		 		 	
				
	For Precigen Inc.:	 		 		 	
				
	 /s/ Helen Sabzevari
	 		 		 	 March 13, 2018

	Helen Sabzevari, Ph.D.	 		 		 	Date
	President, Precigen	 		 		 	
				
	For ZIOPHARM ONCOLOGY INC.:	 		 		 	
				
	 /s/ Kevin Lafond
	 		 		 	 23 Mar 2018

	Name: Kevin Lafond	 		 		 	Date
	Title:   SVP, Finance, CAO	 		 		 	
				
	For Intrexon Corporation:	 		 		 	
				
	 /s/ Jeffrey Perez
	 		 		 	 March 12, 2018

	Jeffrey Perez	 		 		 	Date
	SVP, Intellectual Property Affairs	 		 		 	

  
 Page 4 of 4EX-10.3

 Exhibit 10.3 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)
WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. 
 Confidential 

Amendment #2 

Cooperative Research and Development Agreement # 03111 

“Development and Evaluation of Ziopharm Oncology, Inc.’s Proprietary Non-viral Sleeping Beauty Vectors for
Genetic Modification of Peripheral Blood Lymphocytes with Genes Encoding Mutated Tumor Neoantigen-specific T Cell Receptors (also referred to as Mutation Reactive T Cell Receptors) that Have Been Identified Using NCI Proprietary Methods” 

IC Principal Investigator: Steven A. Rosenberg, M.D., Ph.D. 

Collaborators: Precigen, Inc. and Ziopharm Oncology, Inc. 
 The
purpose of this amendment is to change certain terms of the above-referenced Cooperative Research and Development Agreement (CRADA). These changes are reflected below, and except for these changes, all other provisions of the original CRADA and
Amendment #1 remain in full force and effect. Upon execution, NCI, Precigen Inc., and Ziopharm Oncology, Inc. will each retain a copy of this amendment. Underlining indicates additions, and strikeout indicates deletions. 

The Parties agree: 
  

	 	1.	 Pursuant to that certain Exclusive License Agreement by and between Ziopharm Oncology, Inc., Precigen, Inc.,
and Intrexon Corporation, dated October 5, 2018, Precigen, Inc. has agreed to assign to Ziopharm Oncology Inc. all of Precigen Inc.’s rights, titles and interests in the CRADA. Thus, Precigen, Inc. hereby assigns all of its rights, titles,
interests and benefits in and to CRADA #03111 to Ziopharm Oncology, Inc. In addition, Precigen, Inc. hereby assigns, and Ziopharm Oncology, Inc. hereby assumes, all of Precigen Inc.’s responsibilities under CRADA #03111 accruing on or
after October 5, 2018. For clarity, Ziopharm Oncology, Inc. and NCI shall release Precigen, Inc. from all duties, claims, obligations and liabilities under CRADA #03111 upon execution of this amendment. 

 

	 	2.	 Precigen, Inc. is removed as a Collaborator, and Ziopharm Oncology, Inc is now the only Collaborator. All
references in the CRADA to Collaborator and Precigen, Inc. shall be deemed to refer to Ziopharm Oncology, Inc. The definition of “Collaborator” is modified as follows: “Collaborator” means Ziopharm Oncology, Inc.
as the context dictates, collectively, Intrexon and ZIOPHARM, or individually Intrexon or ZIOPHARM. 

  

	 	3.	 Upon final signature, the term of the CRADA is extended for two (2) years from January 9, 2020 to
January 9, 2022. 

  

	 	4.	 The CRADA title is modified to read as follows: “Development and Evaluation of Precigen
Inc.’s Ziopharm Oncology, Inc.’s Proprietary Non-viral Sleeping Beauty Vectors for Genetic Modification of Peripheral Blood Lymphocytes with Genes Encoding Mutated Tumor
Neoantigen-specific T Cell Receptors (also referred to as Mutation Reactive T Cell Receptors) that Have Been Identified Using NCI Proprietary Methods”. 

  
 Page 1 of
4 

 Confidential 
  

	 	5.	 The CRADA abstract is modified to read as follows: Under a Cooperative Research and Development Agreement
(CRADA), the National Cancer Institute (NCI), Precigen, Inc. and Ziopharm Oncology, Inc. will develop and evaluate adoptive cell transfer-based immunotherapies (ACT) using NCI proprietary methods for the isolation of tumor-reactive
T Cell Receptors (TCRs) targeting unique, patient specific mutated neoantigen(s) and introduction of said TCRs into T cell subsets isolated from peripheral blood using Precigen, Inc. Ziopharm Oncology, Inc. Non-Viral Sleeping Beauty Transposon and Transposases for the treatment of patients with solid tumor malignancies. 

  

	 	6.	 The Contacts Information Page is deleted in its entirety and replaced with the Contacts Information Page in
Exhibit 1. 

 ACCEPTED AND AGREED TO: 

For the National Cancer Institute: 
  

					
	 /s/ James H. Doroshow, M.D.
	 		 	2/1/19
	James H. Doroshow, M.D.	 		 	Date
	Deputy Director for Clinical and Translational Research, NCI	 		 	

 For Precigen Inc.: 
  

					
	 /s/ Donald P. Lehr
	 		 	January 10, 2019
	Name: Donald P. Lehr	 		 	Date
	Title: Director	 		 	

 For Ziopharm Oncology, Inc. 

 

					
	 /s/ Kevin Lafond
	 		 	January 10, 2019
	Name: Kevin Lafond	 		 	Date
	Title: SVP, Finance, CAO	 		 	

  
 Page 2 of
4 

 Confidential 
  

Exhibit 1. 
 CONTACTS
INFORMATION PAGES 
 CRADA Notices 
  

			
	[***]	 	[***]

 Patenting and Licensing 
  

			
	 [***]
	 	 [***]

 Delivery of Materials Identified in Appendix B (if any) 

 

			
	 [***]
	 	 [***]

 [***] = CERTAIN CONFIDENTIAL INFORMATION OMITTED. 

  
 Page 3 of
4 

 Confidential 
  

Finances 
  

			
	 [***]
	 	 [***]

 Clinical Contact (as needed for Article 4.4.2) 

 

			
	 [***]
	 	 [***]

 [***] = CERTAIN CONFIDENTIAL INFORMATION OMITTED. 

  
 Page 4 of
4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00300-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00300-of-00352.parquet"}]]